Synonym: Y06501 Recombinant Human Interleukin-13
Species: Human
Protein Accession: Y06501
Purity: >95%
Endotoxin Level:
<1.0 EU per 1 μg of IL-13
Biological Activity: The ED50 for this effect is typically 0.5-2 ng/mL.
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.
Expression System: Escherichia coli
Fusion Tag: His Tag
Predicted Molecular Mass: Approximately 12 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution in PBS
Reconstitution: Reconstitute the lyophilized recombinant human IL-13
(Y06501) to a concentration of 0.1-1.0 mg/mL in sterile distilled water
Storage & Stability: Store lyophilized protein at -20°C. Aliquot the
product after reconstitution to avoid repeated freezing/thawing cycles.
Reconstituted protein can be stored at 4°C for a limited period of time.
FAQ
What is Y06501 Recombinant Human IL-13 and how does it benefit the feed
industry?
Y06501 Recombinant Human IL-13 is a bioengineered protein that
emulates the natural human interleukin-13 (IL-13). In the feed industry, this
protein can be harnessed to modulate immune responses in livestock, ultimately
improving animal health and productivity. By enhancing the immune system,
animals can better resist diseases, reduce the need for antibiotics, and ensure
a healthier growth environment. IL-13 is known for its role in immune
regulation, reducing inflammation and promoting tissue repair. Incorporating
Y06501 Recombinant Human IL-13 in feed can help achieve more resilient
livestock, potentially leading to higher yields and improved feed conversion
ratios. This means that animals can convert feed into body mass more
efficiently, translating into better weight gain and overall growth
performance.
How does Y06501 Recombinant Human IL-13 contribute to
reducing antibiotic usage in livestock?
The incorporation of Y06501
Recombinant Human IL-13 in animal feed helps to bolster the immune system,
making animals more resistant to infections. A robust immune system decreases
the likelihood of disease outbreaks, reducing the reliance on antibiotics for
disease prevention and treatment. By creating healthier livestock through immune
modulation, producers can minimize the prevalence of antibiotic resistance—a
significant concern in the industry today. As animals become less prone to
infections due to the enhanced immune response facilitated by IL-13, the
necessity for routine antibiotic use diminishes. This aligns with global efforts
to reduce antibiotic use in livestock, promoting more sustainable and
responsible farming practices.
Can Y06501 Recombinant Human IL-13 impact
growth performance and feed efficiency in livestock?
Yes, Y06501
Recombinant Human IL-13 can positively affect growth performance and feed
efficiency. By improving the overall health and immune status of livestock,
animals can allocate more energy towards growth rather than fighting off
diseases. Enhanced immune function and reduced inflammation contribute to better
nutrient utilization, leading to improved feed conversion ratios. This means
that animals can grow faster and more efficiently using the same amount of feed,
optimizing productivity. Therefore, the use of Y06501 Recombinant Human IL-13 in
feed formulations can result in higher weight gains, better feed efficiency, and
potentially reduced feeding costs.
What are the potential environmental
benefits of using Y06501 Recombinant Human IL-13 in livestock
feed?
Utilizing Y06501 Recombinant Human IL-13 in livestock feed can have
several environmental benefits. Improved feed efficiency means that animals
require less feed to achieve the same growth, resulting in lower overall feed
consumption. This not only reduces the demand for agricultural crops used in
animal feed but also decreases the associated environmental footprint, including
land use, water use, and greenhouse gas emissions. Additionally, healthier
animals with stronger immune systems produce less waste and have fewer disease
outbreaks, which can reduce environmental contamination from veterinary
medicines and disease management practices. Thus, the integration of Y06501 can
contribute to more sustainable and environmentally friendly livestock production
systems.
Are there any specific livestock species that benefit more from
Y06501 Recombinant Human IL-13?
Y06501 Recombinant Human IL-13 can be
beneficial across various livestock species, including poultry, swine, and
cattle. However, the specific impact may vary depending on the species and their
unique immune system dynamics. For instance, poultry, which often face
challenges related to respiratory and gastrointestinal diseases, may experience
significant health improvements and better growth performance with the inclusion
of IL-13. Swine, susceptible to various infectious diseases during different
production stages, can also benefit from enhanced immune modulation. Similarly,
cattle, particularly dairy and beef cattle, can see improvements in overall
health, milk production, and meat quality. Therefore, while Y06501 is broadly
beneficial, the particular advantages may be more pronounced in certain species
depending on their specific health challenges and production systems.